Phase II Bevacizumab + Tax In Advanced Breast Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from
dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block
cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
Others find cancer cells and help kill them or deliver cancer-killing substances to them.
Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells.
PURPOSE: This randomized phase II trial is to see if docetaxel with or without bevacizumab
followed by surgery, radiation therapy, and combination chemotherapy works better in treating
patients who have stage III or stage IV breast cancer.